Literature DB >> 10791395

The taxanes: an update.

J Crown1, M O'Leary.   

Abstract

The taxanes are anticancer cytotoxics that stabilise cellular microtubules. Two members, paclitaxel and docetaxel have substantial activity. One or both agents are widely accepted as evidence-based components of therapy for advanced breast, lung, and ovarian carcinomas. Paclitaxel has recently been approved in the USA for the adjuvant treatment of early stage node-positive breast carcinoma.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10791395     DOI： 10.1016/S0140-6736(00)02074-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  78 in total

1.  Docetaxel induced cardiotoxicity.

Authors:  M Shimoyama; Y Murata; K I Sumi; R Hamazoe; I Komuro
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

2.  Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice.

Authors:  O W Nielsen; J Hilden; J F Hansen
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

3.  Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study.

Authors:  N P Gall; M T Kearney; A Zaman; S O'Nunain; K A Fox; A Flapan; J Nolan
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

4.  Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease.

Authors:  C Berry; N Anderson; A J Kirk; A F Dominiczak; J J McMurray
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

5.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

Review 6.  Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.

Authors:  Susana Patricia Egusquiaguirre; Manuela Igartua; Rosa María Hernández; José Luis Pedraz
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

Review 7.  Pregnane X receptor and natural products: beyond drug-drug interactions.

Authors:  Jeff L Staudinger; Xunshan Ding; Kristin Lichti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

8.  Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues.

Authors:  Thota Ganesh; Chao Yang; Andrew Norris; Tom Glass; Susan Bane; Rudravajhala Ravindra; Abhijit Banerjee; Belhu Metaferia; Shala L Thomas; Paraskevi Giannakakou; Ana A Alcaraz; Ami S Lakdawala; James P Snyder; David G I Kingston
Journal:  J Med Chem       Date:  2007-01-31       Impact factor: 7.446

9.  Docetaxel-induced nail changes--a neurogenic mechanism: a case report.

Authors:  Gunnar Wasner; Felix Hilpert; Jörn Schattschneider; Andreas Binder; Jacobus Pfisterer; Ralf Baron
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

10.  Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.

Authors:  Seneha Santoshi; Naresh Kumar Manchukonda; Charu Suri; Manya Sharma; Balasubramanian Sridhar; Silja Joseph; Manu Lopus; Srinivas Kantevari; Iswar Baitharu; Pradeep Kumar Naik
Journal:  J Comput Aided Mol Des       Date:  2014-12-07       Impact factor: 3.686
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.